FTO and nonpapillary renal cell carcinoma: Altogether, our study demonstrates FTO acts as a crucial oncogene in ccRCC through the m6A/YTHDF2/PDK1 pathway, which might be helpful to understand the molecular mechanism in ccRCC progression and unveil potential promising targets for therapy.